Roche is launching a Phase 3 clinical trial to evaluate the ability of its investigational antibody therapy, gantenerumab, to slow Alzheimer’s progression in people with early signs of the disease, the company announced. Called SKYLINE (NCT05256134), the trial is now recruiting 1,200 cognitively unimpaired participants between ages 60 and 80 who show signs of brain amyloid accumulation — an indicator of Alzheimer’s. Recruiting is currently open at two sites in Florida; Roche anticipates opening the…
You must be logged in to read/download the full post.
The post Roche Moving Gantenerumab Into Phase 3 Prevention Trial for Early Alzheimer’s appeared first on BioNewsFeeds.